Astellas Pharma Inc. (TSE:4503) has been making various strategic moves to secure its position in the global biotech market. It has announced a dividend, entered into partnership agreements with AviadoBio and Sangamo Therapeutics for gene therapy, contracted Axcelead DDP for drug discovery service, and launched a cooperative research with UMass Chan Medical School. Controversies have arisen as an employee is indicted by China's prosecutors. Astellas has also initiated initiatives in Tanzania and integrated
DIGITIVA™, a digital solution for heart failure management, with Desert Oasis Healthcare. Astellas' robust involvement in oncology is also worth spotlighting, with new life sciences centers set up in
Cambridge and South
San Francisco. Furthermore, Astellas joined with Takeda and Sumitomo Mitsui Banking to incubate early drug discovery programs. It secured FDA approval for the gastric cancer therapy 'VYLOY™ (zolbetuximab-clzb)', whereas had to withdraw its ACP application for AMD treatment in Europe. Recently, it named Michael Petroutsas as Head of US Commercial and announced cutting 24 Universal Cells roles in Seattle, transferring 12 to Japan.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Fri, 03 Jan 2025 23:14:20 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor 2
